63.21MMarket Cap-0.80P/E (TTM)
0.7645High0.6800Low65.57KVolume0.7645Open0.7645Pre Close47.02KTurnover0.17%Turnover RatioLossP/E (Static)89.70MShares2.750052wk High0.75P/B28.00MFloat Cap0.680052wk Low--Dividend TTM39.74MShs Float10.8700Historical High--Div YieldTTM11.05%Amplitude0.4700Historical Low0.7170Avg Price1Lot Size
Context Therapeutics Stock Forum
“Life-Saving Opoid Overdose Nasal Spray”
4.72 mil free float
゚* ҉* ੈ‧₊ 。゚not financial advice ⋆⋆♡
PR Newswire· 5 mins ago
PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, has been dosed in the first patient in a Phase 1 clinical trial by its licensing partner, Context Therapeutics Inc. Th...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
📊⚡️📊
CTIM-76's development targets a significant unmet need in CLDN6-positive cancers. The bispecific antibody's mechanism of action, engaging T cells to target CLDN6-expressing tumor cells, represents a sophisticated approach in immuno-oncology. Recent SITC presentation data supporting the first-in-human dose selection indicates robust preclinical validation.
For investors, thi...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Tuesday, 14th January at 4:58 pm
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today anno...
No comment yet